The RASopathies are a complex group of conditions regarding phenotype and genetic etiology.
described as clinically distinct syndromes and strong correlations have been noted between each individual syndrome and a mutated gene (s) or even a specific allele within a gene. Despite these correlations, these conditions share a considerable amount of overlapping phenotypic features that can complicate clinical diagnoses. Furthermore, variable expressivity has been described in individuals and families sharing the same genotype (Allanson & Roberts, 1993; Tartaglia et al., 2002) . Therefore, the ClinGen RASopathy expert panel (RAS EP) sought to evaluate the current evidence for each gene-condition assertion in order to provide a comprehensive review of Ras/MAPK pathway genes and their causality of a RASopathy condition.
The ClinGen gene curation effort provides formal evidence-based classifications for the association of a gene with a given disease. This type of information is extremely important as clinicians often use molecular testing results to confirm a clinical diagnosis. Therefore, knowing the level of association of a gene with disease can facilitate more accurate clinical diagnoses. This information also allows for more accurate clinical utility and sensitivity in diagnostic laboratory test designs for specific clinical indications. For example, this exercise supports the exclusion of testing for genes with insufficient evidence to support an association with a RASopathy while also informing which RASopathy genes should be included when testing for specific RASopathy conditions (e.g., a CFC panel). While this list of genes does not include the entirety of genes that have been associated with RASopathies to date (e.g., CBL, NF1, and SPRED1 are not included in this exercise), we curated information for 44 gene-disease associations and confirmed that 56 assertions have not yet been made using published genetic data. Having comprehensive and concise panels is crucial for the practice of molecular medicine, and gene curation has proven to be useful in this endeavor (Strande et al., 2017) .
For certain gene-disease associations, extracting accurate and clear phenotypic information from the literature can be challenging; however, the phenotypic and genetic heterogeneity within the RASopathies is particularly confounding for establishing clear gene associations with specific RASopathy conditions. Due to variable expression and high clinical overlap of the features, clinicians who diagnose RASopathy patients have often used the molecular diagnosis to support a specific phenotypic diagnosis in their patients. For example, if a patient displays phenotypes that overlap between NS and CFC syndrome, they may use the finding of a de novo variant in MAP2K2 as supporting evidence that the patient has CFC instead of relying on specific clinical features. While this exemplifies the utility of molecular medicine as a tool for diagnosis, it also highlights the bias for certain genes to be traditionally associated to only certain RASopathy conditions. However, given that the complexities of the pathway have not been studied in enough detail to rule out that certain MAP2K2 variants may lead to NS, it is useful to note when evidence supports that a patient with a MAP2K2 variant may have NS and not CFC.
While a major part of the utility of the gene curation framework lies in acknowledging all potential associations, RASopathy disorders may have distinguishing features that vary either due to the age of clinical presentation and assessment, generalized phenotypic heterogeneity, or even potentially biased ascertainment. Given these phenotypic similarities overall, a patient diagnosed initially with one entity may transition to a different clinical diagnosis over time as different features manifest or clinical diagnoses are refined. Despite this, there are some nuances and notable differences that can be made among these disorders (see Table 1 ). For example, feature, such as hypertrophic cardiomyopathy is observed across all RASopathies, yet is more commonly observed in patients clinically diagnosed with Costello syndrome (CS; MIM# 218040) or NS with multiple lentigines (NSML; MIM# 151100).
In general, multiple lentigines are very common, but within the context of a RASopathy they are highly correlated to NSML. Certain hematologic or oncologic manifestations, including solid tumors and transitional cell carcinoma, are highly specific for CS (Table 1) . Through systematic collection of published literature and other case-level evidence from diagnostic and research laboratories, these nuances and differences in conditions enable a better understanding of the larger phenotypic spectrum for each gene. The evidence curated by ClinGen can highlight for clinicians which condition(s) have been associated with a gene, and therefore which phenotypic features any given patient may be at risk for. While, we evaluated case evidence in the context of historically well-described, traditional clinical diagnoses that are distinct in the published literature, it was evident that a certain number of cases diverged from these diagnoses when correlated to molecular results. This underscores the need for better nosology in the RASopathy field to refine and reduce diagnostic discrepancies between physicians. Currently, another initiative to tackle this complex issue in conjunction with feedback from the clinical, research, and patient communities is underway.
We curated evidence for the association of 19 genes with five specific RASopathy conditions: NS, CFC, CS, NSML, and Noonan-like syndrome with loose anagen hair (NS/LAH; MIM# 607721). To limit the scope and enable for community feedback of this pilot initiative, our gene list primarily consisted of genes typically associated with a gainof-function (GOF) mechanism leading to a RASopathy in the literature. While many of the gene-disease classifications were curated as definitive and historically linked, we also evaluated genes recently linked to RASopathies, for example, PPP1CB and LZTR1, with the aid of additional diagnostic laboratory data publicly available within ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/). Note, while some phenotype information is provided in ClinVar, additional information was obtained by directly contacting the clinical lab (GeneDx, Gaithersburg, MD). This internal data did not contribute to any divergent classifications, but were found to support the most common disease association for each gene. All divergent assertions evaluated here were found in published literature. We believe that our expert-approved gene-disease validity classifications will be highly informative to patients, researchers, and clinicians interested in the gene-disease associations in the field of RASopathies.
METHODS
The associations of each of the 19 genes were classified using the ClinGen Gene Curation Standard Operating Procedures (Version 5) to the following specific RASopathy conditions: NS, NS/LAH, CFC, CS, and NSML (Strande et al., 2017) . This framework involves a TA B L E 1 Clinical features of various RASopathy diseases are listed (Allanson & Roberts, 1993; Gelb & Tartaglia, 1993; Gripp & Lin, 1993; Pierpont et al., 2014; Rauen, 1993; Roberts, Allanson, Tartaglia, & Gelb, 2013; Romano et al., 2010) . Features that may help to discriminate individual entities from each other are grouped into three categories (bold): (1) Common-low specificity (C-LS): relatively common feature (>20%) with low specificity for entity but observed more frequently than in NS; (2) Common-high specificity (C-HS): relatively common feature (>20%) with high specificity for entity compared to other RASopathies; (3) Rare-high specificity (R-HS): rare feature (<20%) with high specificity for entity compared to other RASopathies 
Intellectual deficits
10-30% mild ID >95% mild to severe ID (C-LS)
>90% mild to moderate ID (C-LS)
10-20% mild ID 30-60% mild ID
Nervous system anomalies
Seizures 5-15%, Chiari I malformation (rare)
Seizures 50% (C-LS); hydrocephalus/ cortical atrophy (C-LS); Neuropathy/ corticospinal tract findings (R-HS)
Seizures 20-50%; Chiari I malformation (C-LS), syringomyelia, hydrocephalus; tethered cord Hypertrophic neuropathy (rare)
Ventriculomegaly/ hydrocephalus may be more common than in NS
Musculoskeletal abnormalities
Pectus deformity, joint laxity, scoliosis 10%, frequent muscular hypotonia, pigmented villonodular synovitis (rare)
Severe pes valgus; joint contractures develop after childhood, scoliosis more common (30-40%) Loose joints; severe pes valgus; tight Achilles tendons in later childhood (C-HS); ulnar deviation at the wrist (C-HS); scoliosis more common (> 50%)
Similar to NS Similar to NS

Vision and hearing
Refractive errors, strabismus
Severe vision impairment related to optic nerve abnormalities more common (C-LS)
Similar spectrum as in NS but higher frequencies Each association was classified as definitive (12-18 points with replication), strong (12-18 points), moderate (7-11 points), limited (0.1-6 points), no evidence, disputed, or refuted per the ClinGen Gene Curation criteria (Strande et al., 2017) .
After primary curation by a ClinGen biocurator, the evidence for each association was presented to clinical RASopathy experts from several different institutions for review. The evidence and the current clinical validity classification and interpretation supporting the gene-disease relationship were discussed at length followed by a vote.
If the vote for the classification was unanimous, the association was approved. If the proposed association was unclear or contested, then the association was discussed at length and voting continued until an 80% quorum from all ClinGen RASopathy Expert Panel (RAS EP) members was achieved. In several cases, the RAS EP approved caveat language for describing and refining the term asserting the clinical validity of an association (Supporting Information, Table S1 ). For example, some limited associations (i.e., MAP2K2: NS-only one scored published case) were predicted by experts to be eventually disputed/refuted, and the group stressed that viewers of those marked "limited" associations should exercise caution.
RESULTS
A total of 19 genes were curated for their associations with five specific RASopathy conditions. The genes found to be definitive for at least There were no published case-control studies to score. All genes historically known to participate within the Ras/MAPK pathway or have homologous function to known genes achieved 0.5 points in the functional score based on the well-established biochemical function and protein interactions of the pathway. Due to the ubiquitous expression of these genes, tissue-specific expression did not provide functional evidence to associate these genes with the RASopathies. Strength of evidence associated with animal models and rescue models was typically downgraded to 0.5 points due to the lack of phenotypic specificity in the models for the discrete RASopathy conditions. Functional alterations from observed variants in patient and nonpatient derived cells were assessed stringently for supporting disease causation and were only scored separately when a distinct assay directly supported a unique mechanism or endpoint for the specific condition being assessed. For example, NSML caused by variation in PTPN11 results in a predicted neomorphic allele that has reduced catalytic activity (but is not equivalent to a null allele, which is known to cause metachondromatosis) compared to the standard increased activity associated with PTPN11-related NS variants (Fragale, Tartaglia, Wu, & Gelb, 2004; Kontaridis, Swanson, David, Barford, & Neel, 2006; Noda, Takahashi, Hayashi, Tanuma, & Hatakeyama, 2016; Oishi, Gaengel et al., 2006; Oishi, Zhang et al., 2009; Yu et al., 2014) . Table 2 summarizes the classifications of all curations along with their semiquantitative score for specific RASopathy conditions (maximum out of 18).
DISCUSSION
Gene curation workflow
While we utilized the ClinGen gene curation framework to assess these associations, there were some unique aspects of our process that should be noted. After primary curation, the scored literature evidence was presented to the ClinGen RAS EP for review. It Table S1 ). The
ClinGen RAS EP evaluated the evidence and commented on whether certain cases and experimental data should be scored. They also commented on the status of the current practices in the field and whether certain genes are traditionally thought of as being associated with certain conditions. In some cases, the ClinGen RAS EP asserted that certain associations may not align with current practices or may be inaccurate relative to the context of a particular case. For example, BRAF alterations are traditionally associated with CFC syndrome; however, BRAF alterations have also been identified in patients with features more typical of NS (Lee et al., 2011; Nystrom et al., 2008; Razzaque et al., 2007; Sarkozy et al., 2009; van Trier et al., 2016) .
In these instances, the RAS EP noted that the age of ascertainment, outdatedness of clinical assessments, and variable expressivity of the RASopathies should be considered when scoring these cases. After thorough discussion of the evidence, the RAS EP voted blindly on the classification of the clinical validity of the association. If a consensus was not achieved, the curation was discussed further until at least 80% of the RAS EP was in agreement. In these situations, specific language helped in conveying the reasons for the final decision of the RAS EP (Supporting Information, Table S1 ).
Challenges of the curation process
The RASopathies are a complex group of disorders with substantial overlap across conditions. Additionally, the molecular mechanisms 
a Denotes a gene where publicly available data were used to supplement the published literature. b Denotes a curation that was downgraded by expert opinion or the time/# of publication constraints in the ClinGen Gene Curation framework. AR, autosomal recessive inheritance.
underlying the resultant RASopathy condition are not clearly correlated to specific variation within a gene. Our work highlights which discrete disorders have been shown to be associated with Ras/MAPK genes in the published literature. Unfortunately, a substantial amount of published literature does not provide enough information to differentiate between certain conditions, such as NS versus CFC syndrome.
This limitation is particularly related to the fact that most reported cases are children. Young age at presentation is a significant cause of disputable phenotypic classifications. Since the clinicians on the RAS EP could not clinically evaluate the patients described in publications themselves, we were reliant on the diagnosis provided in the literature.
Our decision to maintain separate associations for each gene and specific condition, instead of only providing a clinical validity classification for each gene's association with a general RASopathy, was challenging. While there is an ongoing discussion in the field of the RASopathies as to whether these genes should be classified as a phenotypic spectrum under a broader disease entity, the clinical diagnoses currently provided to patients is historically supported as separate syndromes. Therefore, we felt it was important that our curations investigated each gene's level of evidence for each of the five discrete syndromes. This allowed us to dispute weaker gene-disease associations that lacked convincing evidence. This process underscored the need for clear nosology guidelines for the RASopathies and the clinicians within the ClinGen RAS EP aimed to highlight specific phenotypic features that can assist in the differentiation of the RASopathies (see Table 1 ).
While we decided that it was important for each curation to assess the clinical validity of the specific conditions, we found that almost individual with a BRAF mutation and cognitive function in the normal or low-normal range is more likely to be clinically classified as NS.
Since there are several gene-disease associations that are considered uncommon in the field of RASopathies (e.g., the associations of KRAS with Costello and MAP2K1 with NS) many of the associations were disputed by our curations. However, if variants in the gene were associated with an "uncommon" disease but identified in a distinct risk profile within the phenotypic spectrum associated with this disease, the RAS EP typically deferred to the calculated classification of limited or moderate evidence, instead of disputing the association. In contrast, if an uncommon disease association was reported for a variant that had repeatedly been observed with the commonly-associated disease for its respective gene, the uncommon association was classified as disputed. This applies, for example, to the associations of CFC syndrome with PTPN11, SHOC2, and RAF1.
Examples of challenging curations
There were several curations in which the lack of clear genotypephenotype correlations merited careful review in the scoring of genetic evidence to support an association. Additionally, the identification of the same variant linked to multiple conditions revealed the lack of specificity in molecular evaluations to a given condition, yet still supported a general association to a RASopathy. Some examples are shown below but further details are provided in Supporting Information, Table S1 .
KRAS-CFC syndrome
KRAS is traditionally associated with NS, but KRAS variants have also been identified in patients with a clinical diagnosis of CFC. Additionally, there is substantial phenotypic overlap between NS and CFC syndrome. For example, the cardiac abnormalities and facial anomalies possess a very similar spectrum (Table 1) . While the severity of intellectual disability, frequency of severe ectodermal anomalies, and presence of neuropathy or other corticospinal tract anomalies can be used to differentiate NS from CFC syndrome, these distinguishing features can still be observed in NS and are age dependent. Therefore, despite sufficient genetic evidence and repetition over time for KRAS and CFC syndrome to establish a definitive classification, these complexities led clinicians in the RAS EP to caution against classifying CFC syndrome as definitively associated with KRAS. The RAS EP chose to classify the association as strong.
With the evidence provided in the literature, it was not always convincing to the RAS EP that a case described as CFC syndrome with a KRAS variant would not develop features more consistent with NS over time due to the fact that many of the patients were less than 10 years of age ( et al., 2007) . Of note, there were cases in the literature who were as old as 26 presenting with features more consistent with CFC syndrome (Sovik et al., 2007) . This scenario exemplifies that a molecular diagnosis should not dictate the final clinical diagnosis, but encourage clinicians to scrutinize the phenotypic presentation of the individual over time. While our consistent approach was to accept the diagnoses within the peer-reviewed literature provided and score cases if the variants themselves had sufficient evidence for pathogenicity, in this particular case, the RAS EP decided that the uncertainty surrounding the cases provided exceptional reasons to downgrade the classification from definitive to strong. We cite variant overlap between CFC syndrome and NS patients, variable expressivity, outdated assessments, and young age of ascertainment of diagnoses of affected individuals as reasons for downgrading this classification from definitive to strong (Supporting Information, Table S1 ).
LZTR1 Associations
LZTR1 is a gene that has been more recently (< 3 years from first publication) associated with the RASopathies. The published cases to date have presented with features consistent with NS; however, the mechanism of inheritance is variable. Autosomal dominant (AD) variants are exclusively missense Yamamoto et al., 2015) , while the autosomal recessive (AR) variants are predominantly predicted loss-of-function (LOF) with at least one hypomorphic allele being present in patients with biallelic mutations (Johnston et al., 2018) . It could be inferred that biallelic LOF or a GOF, potentially as dominant negative mechanism, missense variant can lead to the Noonan condition. Of note, LZTR1 is not LOF constrained according to Exome Aggregation Consortium (ExAC) data, suggesting that these variants may be tolerated (exac.broadinstitute.org) (Lek et al., 2016) .
Further identification and publication of LZTR1 RASopathy cases are necessary to further confirm these disease mechanisms. Given that variants in LZTR1 have been shown to segregate with an NS condition in both inheritance patterns and apparently due to different disease mechanisms, we chose to split the curations into scores for both the AR and AD associations of LZTR1 with the RASopathies. Furthermore, since there have only been three publications to date, we utilized publicly available, yet not formally published data from diagnostic laboratories in ClinVar to achieve the most up-to-date evidence score that reflects the current acceptable association in the field. Evidence of multiple confirmed de novo occurrences primarily justified the score of 12 for genetic evidence. Lack of experimental evidence and replication over time prevents a definitive association, thus the AD association is currently assessed as strong, but is expected to move to definitive in the near future if no contradictory evidence emerges.
BRAF/MAP2K1/MAP2K2: Noonan syndrome
Variants in these genes have repeatedly been associated with NS, but in many publications, the rationale and basis for the clinical diagnosis of NS over CFC is unclear. As mentioned previously, many of the variants associated with NS in these genes have also been reported in association with CFC. This may be further complicated by the lack of consensus criteria and nosology for differentiating NS from CFC syndrome clinically. Moreover, functional differences between NS-and CFC syndrome-associated BRAF/MAP2K1/MAP2K2 variants have not been established, so far. These reasons may support categorizing and classifying these genes with a broader disease entity that encompasses both NS and CFC (i.e., a RASopathy), but the RAS EP felt it was necessary to maintain the traditional disease conditions and assess the strength of evidence for each condition associated with these genes in the literature. It should be noted that none of the associations of these genes with NS reached the maximum score for genetic evidence, thus indicating further evaluation of evidence is needed in the future.
The RAS EP noted that some variants in BRAF and MAP2K1 were consistently associated with NS alone while other variants had broader assertions, indicating the potential for specific genotype-phenotype correlations to be elucidated over time with further experimentation and exploration through functional assays. The RAS EP recognized that the NS diagnosis in individuals carrying variants in genes typically associated with CFC syndrome is a major point of discussion when attempting to classify gene-disease associations among RASopathies.
The RAS EP asserted that a phenotypic diagnosis based exclusively on the molecular diagnosis from a gene (and not genotype) level in this area would not appropriately reflect the broad phenotypic spectrum associated with mutations in BRAF, MAP2K1, and MAP2K2.
PTPN11/BRAF/RAF1: NSML
There is a definitive association for PTPN11 variants with NSML.
Unlike other associations, there is robust evidence for the major NSML-associated PTPN11 variants (p.Y279C and p.T468M) displaying clearly different functional properties (reduced phosphatase activity) compared to NS-associated variants. However, this has not been shown for all NSML-associated PTPN11 variants (Fragale et al., 2004; Kontaridis et al., 2006; Noda et al., 2016; Oishi, Gaengel et al., 2006; Oishi, Zhang et al., 2009; Yu et al., 2014) . Moreover, young individuals lack clear distinguishing phenotypic characteristics between NS
and NSML so precise diagnoses may be difficult, thus explaining the reported associations of NS with "classical" NSML-associated variants in the literature. In addition to the distinct functional impact of NSMLassociated PTPN11 variants, there is also a risk profile that distinguishes NSML from NS (e.g., high risk of hypertrophic cardiomyopathy (HCM), risk of hearing deficits). The differentiation is less clear for BRAF and RAF1-associations with NSML, and no specific functional impact of NSML-associated BRAF/RAF1 variants has been established in these genes. Furthermore, the RAS EP asserted from their own experience that even the skin phenotype associated with BRAF and RAF1 is distinct from the multiple lentigines phenotype seen in patients with "classical" NSML-related PTPN11 variants.
SHOC2 with NS/CFC syndrome and CS
Primary curation showed "limited" evidence for an association of SHOC2 with NS, CFC syndrome and CS. After discussion, the RAS EP decided to classify all other disease associations for SHOC2 except NS/LAH as disputed given the primary common pathogenic variant (p.Ser2Gly) in this gene has been reported over 100 times with a clinical diagnosis of NS/LAH. In addition, this mutation has distinct functional consequences, and the resemblance of the condition associated with variants in PPP1CB, a known direct interaction partner with SHOC2, further supports that NS/LAH is a discrete entity specifically related to alterations in this signaling complex module (Aoki, Niihori, Inoue, & Matsubara, 2016; Rauen, 2013 
CONCLUSIONS
Given the complexities surrounding the RASopathies, we believe that our curation process's thorough assessment of the current published 
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